Malignant pleural mesothelioma (MPM) is an aggressive cancer with poor prognosis. Systemic chemotherapy is the primary treatment modality for the majority of patients. VEGF plays a key mitogen for MPM cells physiopathology. Bevacizumab, a monoclonal anti-VEGF antibody, was a rational approach to be tested in MPM. Based on the results of the Phase III IFCT-0701 mesothelioma avastin cisplatin pemetrexed study, cisplatin-pemetrexed-bevacizumab is now the accepted standard in France. The National Comprehensive Cancer Network guidelines have also included this combination as an option for standard front-line therapy. This review summarized the efficacy and safety data of bevacizumab in the treatment of patients with MPM.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2217/fon-2017-0307 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Patterns of immune evasion in triple-negative breast cancer and new potential therapeutic targets: a review.
Front Immunol
December 2024
Medical Oncology Department, Hospital Arnau de Vilanova, Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO), Valencia, Spain.
Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer characterized by the absence of progesterone and estrogen receptors and low (or absent) HER2 expression. TNBC accounts for 15-20% of all breast cancers. It is associated with younger age, a higher mutational burden, and an increased risk of recurrence and mortality.
View Article and Find Full Text PDFHepatocellular carcinoma converted from atezolizumab and bevacizumab combination therapy: a case report.
Oxf Med Case Reports
December 2024
Department of Gastroenterological and General Surgery, St. Marianna University School of Medicine, 2-16-1 Sugao Miyamae-ku, Kawasaki-shi, Kanagawa-ken 216-8511, Japan.
Hepatectomy is the curative treatment for hepatocellular carcinoma (HCC), with targeted therapy used when resection is difficult. In this rare case, the tumor shrank with targeted therapy, enabling radical treatment through conversion surgery. The patient, a man in his 70s, developed an 11.
View Article and Find Full Text PDFOutcomes after unilateral bevacizumab treatment for infants with asymmetric retinopathy of prematurity.
J AAPOS
December 2024
Department of Ophthalmology, Emory University, Atlanta, Georgia.
In this retrospective study of asymmetric retinopathy of prematurity (ROP) cases treated with unilateral intravitreal bevacizumab (IVB), half of the treated patients did not require further IVB, whereas the other half required sequential IVB at a mean of 12 days after initial treatment.
View Article and Find Full Text PDFA comparation of three different anti-VEGF drugs in development of persistent avascular retina in premature children.
Sci Rep
December 2024
Department of Ophthalmology, University of Health Sciences, Antalya Education and Research Hospital, Antalya, 07050, Turkey.
Our current prospective cross-sectional study aimed to investigate the effect of anti-vascular endothelial growth factor (VEGF) drugs used in the treatment of retinopathy of prematurity on retinal maturation and persistent avascular retina (PAR). Retinal imaging was performed with Optos confocal laser ophthalmoscopy for 100 patients aged 4 to 8 years who were screened and treated for retinopathy of prematurity (ROP) during the neonatal period. The ROP examination findings (stage and zone) and treatment history (age in weeks at time of treatment and anti-VEGF drug used) from the neonatal period were reviewed.
View Article and Find Full Text PDFRisk factors for venous thromboembolism in patients undergoing neoadjuvant chemotherapy as treatment for ovarian cancer.
Eur J Obstet Gynecol Reprod Biol
December 2024
Department of Gynaecological Oncology, West Kent Cancer Centre, Maidstone and Tunbridge Wells NHS Trust, Hermitage Lane, Maidstone, Kent ME16 9QQ, United Kingdom.
Objective: During the treatment of ovarian cancer, the risk of venous thromboembolism (VTE) post operatively is well established, however, patients may be at even greater risk during neoadjuvant chemotherapy (NACT). This study aimed to determine the incidence and timing of VTE amongst patients undergoing NACT, whether there was an association with survival, and examine risk factors associated with the development of VTE.
Study Design: This was a retrospective cohort study of patients diagnosed with ovarian, fallopian tube and primary peritoneal cancer receiving neoadjuvant chemotherapy betweenApril 2011 and April 2022 at a gynaecological cancer centre in England.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!